Intercept Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
CTLTCatalent, Inc. -2.83%74.732.3%$130.41m
MYOKMyoKardia, Inc. -0.60%98.231.8%$125.78m
BHCBausch Health Cos., Inc. -0.72%19.230.0%$125.36m
HZNPHorizon Therapeutics Plc 1.14%48.126.5%$124.56m
VRXValeant Pharmaceuticals International, Inc. -0.72%19.2314.1%$113.15m
UTHRUnited Therapeutics Corp. 1.00%123.6414.3%$78.66m
PTLAPortola Pharmaceuticals, Inc. -0.06%17.916.5%$75.11m
ARGXargenx SE -2.29%225.950.0%$63.49m
ICPTIntercept Pharmaceuticals, Inc. 2.02%77.9216.8%$63.27m
JAZZJazz Pharmaceuticals Plc -1.01%120.652.4%$56.20m
GWPHGW Pharmaceuticals Plc 0.62%128.136.2%$53.62m
AMRNAmarin Corp. Plc -1.18%6.681.6%$50.61m
AXSMAxsome Therapeutics, Inc. 3.89%77.381.9%$47.82m
PRGOPerrigo Co. Plc 0.74%55.646.8%$44.30m
ICLRICON plc -1.39%162.624.3%$39.28m

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.